Citi analyst Joel Beatty downgraded Esperion Therapeutics to Neutral saying he does not expect significant stock moves over the next 12 months with Phase III data for Bempedoic Acid not coming until mid-2018.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here